223 related articles for article (PubMed ID: 34656807)
1. Driving Out Chronic Lymphocytic Leukemia With CAR T Cells.
Kharfan-Dabaja MA; Yassine F; Gadd ME; Qin H
Transplant Cell Ther; 2022 Jan; 28(1):5-17. PubMed ID: 34656807
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
3. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
Fraietta JA; Schwab RD; Maus MV
Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
[TBL] [Abstract][Full Text] [Related]
4. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
Bair SM; Porter DL
Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
[TBL] [Abstract][Full Text] [Related]
7. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
8. Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies.
Luo Y; Qie Y; Gadd ME; Manna A; Rivera-Valentin R; To T; Li S; Yassine F; Murthy HS; Dronca R; Kharfan-Dabaja MA; Qin H
Cancer Immunol Immunother; 2023 Dec; 72(12):4031-4047. PubMed ID: 37814001
[TBL] [Abstract][Full Text] [Related]
9. Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia.
Mancikova V; Smida M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073911
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.
Zou Y; Xu W; Li J
J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878
[TBL] [Abstract][Full Text] [Related]
11. CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.
Todorovic Z; Todorovic D; Markovic V; Ladjevac N; Zdravkovic N; Djurdjevic P; Arsenijevic N; Milovanovic M; Arsenijevic A; Milovanovic J
Curr Oncol; 2022 May; 29(5):3647-3657. PubMed ID: 35621683
[TBL] [Abstract][Full Text] [Related]
12. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
Al-Juhaishi T; Ahmed S
Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Tettamanti S; Rotiroti MC; Giordano Attianese GMP; Arcangeli S; Zhang R; Banerjee P; Galletti G; McManus S; Mazza M; Nicolini F; Martinelli G; Ivan C; Veliz Rodriguez T; Barbaglio F; Scarfò L; Ponzoni M; Wierda W; Gandhi V; Keating M; Biondi A; Caligaris-Cappio F; Biagi E; Ghia P; Bertilaccio MTS
Leuk Lymphoma; 2022 Jul; 63(7):1566-1579. PubMed ID: 35259043
[TBL] [Abstract][Full Text] [Related]
15. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract][Full Text] [Related]
16. Challenges and opportunities of CAR T-cell therapies for CLL.
Zhao Z; Grégoire C; Oliveira B; Chung K; Melenhorst JJ
Semin Hematol; 2023 Jan; 60(1):25-33. PubMed ID: 37080707
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?
Davila ML; Brentjens R
Hematol Oncol Clin North Am; 2013 Apr; 27(2):341-53. PubMed ID: 23561477
[TBL] [Abstract][Full Text] [Related]
18. [Novel therapy for malignant lymphoma: adoptive immuno-gene therapy using chimeric antigen receptor(CAR)-expressing T lymphocytes].
Ozawa K
Nihon Rinsho; 2014 Mar; 72(3):547-52. PubMed ID: 24724418
[TBL] [Abstract][Full Text] [Related]
19. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
20. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
